GlassScriptPhysician profile
Frank Procaccino
NPI 1477658193
$4,157.39
in general payments reported to CMS, 2019-2025
32 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $69.20 · 2021: $117 · 2022: $444 · 2023: $417 · 2024: $1,079 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,089.08 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $883.16 | 2019-2025 | Xifaxan, Relistor |
| Abbvie INC. | $439.45 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $396.76 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $332.66 | 2019-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $316.78 | 2019-2022 | |
| Pfizer INC. | $217.13 | 2021-2025 | |
| Genzyme Corporation | $185.34 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $138.60 | 2019 | |
| Qol Medical, LLC | $116.37 | 2025 | Sucraid |
| Ardelyx, INC. | $114.36 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $108.73 | 2023-2025 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $103.08 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $94.99 | 2023-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $78.19 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $73.66 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $71.97 | 2023-2025 | Ocaliva |
| Novo Nordisk INC | $54.06 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $47.87 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $43.00 | 2024-2025 | Dupixent |
| Celgene Corporation | $41.52 | 2023-2024 | Zeposia |
| Ethicon US, LLC | $38.49 | 2021 | |
| Alnylam Pharmaceuticals INC. | $36.55 | 2024 | Givlaari |
| Celltrion USA INC. | $31.42 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $29.65 | 2024 | Dificid |
| Sandoz INC. | $24.96 | 2025 | Hyrimoz |
| Exact Sciences Corporation | $24.30 | 2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $23.21 | 2023 | |
| Olympus America INC. | $21.35 | 2019 | |
| Amgen INC. | $20.35 | 2025 | Repatha |
| Lilly USA, LLC | $18.04 | 2025 | Omvoh |
| Evoke Pharma, INC. | $16.56 | 2024 | |
| Pharmacosmos Therapeutics INC. | $14.83 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Procaccino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.